血管紧张素转换酶抑制剂对心力衰竭患者细胞因子干预作用的研究进展

Research of Intervention of Angiotensin-Converting Enzyme Inhibitors to the Cytokines in the Patients with Heart Failure

充血性心力衰竭(congestive heart failure,CHF)是多种心血管疾病所致的一种临床综合征,其病理生理机制除交感神经系统(sympathetic nervous system,SNS)和肾素-血管紧张素-醛固酮系统(rennin-angiotensin-aldosterone system,RAAS)的激活外,细胞因子的激活和失衡也参与了CHF的发生发展过程。有研究证实,血管紧张素转换酶抑制剂(angiotensin convertingenzyme inhibiter,ACEI)不但能阻断SNS及RAAS的激活,还能调整细胞因子网络的失衡,逆转心室肥厚以及防止和延缓心室重构,有助于延缓、遏止CHF进展。本文总结了ACEI对CHF患者血清炎症细胞因子的干预作用的研究现状,探讨通过此途径治疗CHF的效果。

Congestive heart failure （CHF） is a clinical syndrome caused by a variety of cardiovascular diseases. Its pathophysiological mechanism is not only the activation of sympathetic nervous system （SNS） and rennin-angiotensin-aldosterone system （RAAS）, but also the activation and imbalance of cytokine in the development of CHF. Angiotensin converting enzyme inhibiter （ACEI） have been shown to block the activation of this system, reverse myocardial hypertrophy, as well as to prevent and delay the LV remodeling, delay and prevent the progress of CHE This paper summarizes the status research of the intervention of ACEI to the inflammatory cytokines in the patients with CHF, and explores the effects of CHF through this way.